CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression.

By Rhonda L. Brown, Lauren M. Reinke, Marin S. Damerow, D. Perez, L. Chodosh, Jing Yang, Chonghui Cheng. Journal of Clinical Investigation, 2011

624 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/b2c597b1a05b9e44942ea3a37c2b4b3b1feef77e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. M. Nieto
2. R. Weinberg
3. J. P. Thiery
4. A. Cano
5. Jing Yang

In Oncology

1. M. Nieto
2. R. Weinberg
3. J. P. Thiery

Citations in the corpus

• The biology and role of CD44 in cancer progression: therapeutic implications (2018, background): “isoforms switch in breast cancer cells [54].”
• EMT and tumor metastasis (2015, background): “During EMT, Snail inhibits ESRP1, increasing the expression of the CD44 isoform associated with dedifferentiation and invasiveness [37].”
• The ins and outs of the epithelial to mesenchymal transition in health and disease. (2011, background): “ESRP absence also leads to the production of the mesenchymal isoform of surface protein CD44s, which was recently associated with the EMT and metastasis, versus the epithelial CD44v form (Brown et al. 2011).”